An enzyme-modulated oxygen-producing micro-system for regenerative therapeutics.

Int J Pharm

Department of Biomedical Science, Kyungpook National University, Daegu 700-412, Republic of Korea.

Published: May 2011

This study suggests the idea of treating oxygen as a drug in a biological environment and demonstrates that it will exhibit a dosage-dependent trend. To accomplish this, a micro-system was fabricated, having hydrogen peroxide as the oxygen-generating source, which was decomposed using catalase, a common enzyme found in nearly all living organisms. The relevance of the proposed micro-system was justified using cell viability assays under well-controlled and fixed conditions. This study was performed under two controlled conditions, normoxia and hypoxia, and tests were carried out using three different configurations of samples under each condition: direct addition of H(2)O(2), H(2)O(2) encapsulated with single layer, and H(2)O(2) encapsulated with double layers. This study demonstrates that the elegantly designed micro-system managed to control the decomposition of H(2)O(2) and avoided direct contact with cells, while also maintaining cell viability under a low oxygen environment.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijpharm.2011.02.041DOI Listing

Publication Analysis

Top Keywords

cell viability
8
h2o2 encapsulated
8
enzyme-modulated oxygen-producing
4
micro-system
4
oxygen-producing micro-system
4
micro-system regenerative
4
regenerative therapeutics
4
therapeutics study
4
study suggests
4
suggests idea
4

Similar Publications

Discovery of noncovalent diaminopyrimidine-based Inhibitors for glioblastoma via a dual FAK/DNA targeting strategy.

Eur J Med Chem

January 2025

School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China. Electronic address:

Temozolomide, a widely used alkylating agent for glioblastoma treatment, faces significant challenges due to the development of resistance, which severely impacts patient survival. This underscores the urgent need for novel strategies to overcome this barrier. Focal adhesion kinase (FAK), an intracellular non-receptor tyrosine kinase, is highly expressed in glioblastoma cells and has been identified as a promising therapeutic target for anti-glioblastoma drug development.

View Article and Find Full Text PDF

The objective of this study was to investigate the prognostic significance of the frequency of primary cilia (PC) and β-catenin expression in 218 patients (pts) with non-small cell lung cancer (NSCLC), including 125 pts with adenocarcinoma and 93 pts with squamous cell carcinoma. In the whole group of 218 pts with NSCLC, overall survival (OS) was significantly inferior among pts with present PC than without PC (p=0.024) and with higher cytoplasmic β-catenin expression (25-75%) than with lower cytoplasmic β-catenin expression (<25%) (p=0.

View Article and Find Full Text PDF

Background: Centromere protein N (CENPN), located on chromosome 16q23.2, encodes vital nucleosome-associated complexes that are essential for dynamic assembly processes. CENPN plays a pivotal role in regulating cell proliferation and cell cycle progression by influencing mitotic events.

View Article and Find Full Text PDF

Neurodegenerative diseases (NDs) are caused by progressive neuronal death and cognitive decline. Epigallocatechin 3-gallate (EGCG) is a polyphenolic molecule in green tea as a neuroprotective agent. This review evaluates the therapeutic effects of EGCG and explores the molecular mechanisms that show its neuroprotective properties.

View Article and Find Full Text PDF

Opioids are the primary regimens for perioperative analgesia with controversial effects on oncological survival. The underlying mechanism remains unexplored. This study developed survival-related gene co-expression networks based on RNA-seq and clinical characteristics from TCGA cohort.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!